Costas Lyssiotis, Ph.D.

Assistant Professor, Molecular & Integrative Physiology
Department of Internal Medicine, Division of Gastroenterology


Costas A. Lyssiotis obtained his bachelor’s degree in Chemistry and Biochemistry from the University of Michigan in 2004, his PhD in Chemical Biology from The Scripps Research Institute in 2010, and then completed postdoctoral training in the laboratory of Lewis C. Cantley at Harvard and Cornell. In 2015, Dr. Lyssiotis joined the faculty at the University of Michigan with appointments in the Departments of Physiology and Medicine. His lab studies the biochemical pathways and metabolic requirements that enable tumor survival and growth. This work spans the areas of cancer metabolism, the tumor microenvironment and immunometabolism using and developing protocols in mass spectrometry-based metabolomics. Ultimately, his group aims to transition new information about these processes into targeted therapies for cancer and other diseases. He is the recipient of several junior scholar awards including being named a Lefkofsky Scholar, a Kimmel Scholar, an AACR NextGen young investigator, a Dale F. Frey Breakthrough Scientist, and a V Foundation Fellow.

Research Interests

Tumor Metabolism, Cancer, Pancreatic Cancer, Immunometabolism, Metabolomics, Autoimmunity


Lyssiotis CA, Kimmelman AC. Metabolic Interactions in the Tumor Microenvironment. Trends in Cell Biology (2017).

Halbrook CJ, Lyssiotis CA. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. Cancer Cell (2017) 31:5-19. 

Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, †Lyssiotis CA [†co-senior authors], †Kimmelman AC. Pancreatic Stellate Cells Support Tumour Metabolism Through Autophagic Alanine Secretion. Nature (2016) 25, 479-483.

Chakrabarti G, Moore Z, Luo X, Ilcheva M, Ali A, Anderson GG, Padanad M, Scaglioni PP, Cantley LC, Kimmelman AC, DeBerardinis RJ, †Lyssiotis CA [†co-senior authors], †Boothman DA. Targeting Glutamine Metabolism Sensitizes Pancreatic Cancer to PARP1-driven Metabolic Catastrophe Induced by ß-lapachone. Cancer & Metabolism (2015) 3, 12.

*Son J, *Lyssiotis CA [*co-lead authors], Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC & Kimmelman AC. Glutamine Supports Pancreatic Cancer Growth Through a KRAS-Regulated Metabolic Pathway. Nature (2013) 496, 101–105.